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Abstract
Background: Despite of an increasing body of research the associations between vitamin B12 and
folate levels and the treatment outcome in depressive disorders are still unsolved. We therefore
conducted this naturalistic prospective follow-up study. Our aim was to determine whether there
were any associations between the vitamin B12 and folate level and the six-month treatment
outcome in patients with major depressive disorder. Because vitamin B12 and folate deficiency may
result in changes in haematological indices, including mean corpuscular volume, red blood cell
count and hematocrit, we also examined whether these indices were associated with the treatment
outcome.
Methods:  Haematological indices, erythrocyte folate and serum vitamin B12  levels were
determined in 115 outpatients with DSM-III-R major depressive disorder at baseline and serum
vitamin B12 level again on six-month follow-up. The 17-item Hamilton Depression Rating Scale was
also compiled, respectively. In the statistical analysis we used chi-squared test, Pearson's
correlation coefficient, the Student's t-test, analysis of variance (ANOVA), and univariate and
multivariate linear regression analysis.
Results: Higher vitamin B12 levels significantly associated with a better outcome. The association
between the folate level and treatment outcome was weak and probably not independent. No
relationship was found between haematological indices and the six-month outcome.
Conclusion: The vitamin B12 level and the probability of recovery from major depression may be
positively associated. Nevertheless, further studies are suggested to confirm this finding.
Background
Low levels of vitamin B12 and folate have been found in
the serum and red blood cells of patients with depressive
disorders [1-4]. Older, physically disabled women with
metabolically significant vitamin B12deficiency have been
found to have a two-fold higher risk of depression than
women with normal plasma levels of vitamin B12 [5]. The
findings from three recent large population-based studies
are, however, contradictory [6-8].
A Dutch study (n = 3884) suggested that B12 deficiency but
not folate deficiency is independently related to depres-
sive disorders [6]. Morris et al. [7] found a low folate sta-
tus in depressed subjects in a sample of the general US
population (n = 2948). Finally, a Norwegian study (n =
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5948) suggested that neither low plasma folate nor vita-
min B12 levels are significantly related to depression with-
out comorbid anxiety disorder in the general population
[8].
A low folate level has been linked to a poor response to
antidepressive drug therapy [4,9,10], and daily folic acid
or methylfolate augmentation of antidepressive drug
treatment has been reported to improve clinical and social
recovery [11-14]. Thus far, no associations have been
found between a low vitamin B12 level and a poor treat-
ment response in patients with depressive disorders. Nev-
ertheless, the augmentation of antidepressive treatment
with vitamins B1, B2, and B6 increased vitamin B12 levels in
elderly patients with major depression without specific
supplementation, and there were trends towards greater
improvements in scores for depression ratings [15].
The clinical relevance of these findings concerning the
associations between vitamin B12 and folate levels and the
treatment outcome in depressive disorders is still
unsolved. We therefore conducted this naturalistic pro-
spective follow-up study. Our aim was to determine
whether there were any associations between the vitamin
B12 and folate level and the six-month treatment outcome
in patients with major depressive disorder in Finland.
Because vitamin B12 and folate deficiency may result in
changes in haematological indices, including mean cor-
puscular volume, red blood cell count and hematocrit, we
also examined whether these indices were associated with
the treatment outcome. On the basis of previous studies
we hypothesized that both high vitamin B12 and folate
levels might be positively associated with a better treat-
ment outcome in patients with major depressive disorder.
Methods
The subjects were 115 outpatients with DSM-III-R major
depressive disorder consecutively consulted in the Depart-
ment of Psychiatry, Kuopio University Hospital, Finland.
Approval for the study was obtained from the Ethics Com-
mittee of Kuopio University Hospital and the University
of Kuopio. All patients provided written informed consent
before entering the study.
At entry, the diagnosis of a current episode of major
depressive disorder was confirmed by means of the Struc-
tured Clinical Interview for DSM-III-R, conducted by a
trained interviewer [16]. Patients completed question-
naires relating to their sociodemographic background,
current smoking habits (yes/no), patterns of alcohol use
(used at least once a week/other), family history of depres-
sion (one or both parents have been treated for depres-
sion; yes/no) and the duration of depressive illness (years
from the first episode of depressive symptoms). Patients'
weights and heights were also measured, and body mass
index (BMI) was calculated.
There were 70 females (61%) and 45 males (39%) in the
sample, with a mean age of 43.9 (SD 10.9, range 21 – 69)
years. Thirty-one of the patients (27%) had a positive fam-
ily history of depressive disorders. The first episode of
depressive symptoms had occurred on average 9.6 (SD
10.2) years before. Twenty-four per cent of the patients
were current smokers (n = 27) and twenty-six per cent
used alcohol weekly (n = 30). None of these variables
associated with the treatment outcome (see classification
later).
At entry, the serum vitamin B12 and erythrocyte folate
level as well as haemoglobin (Hb), mean corpuscular vol-
ume (MCV), red blood cell count (RBC) and hematocrit
(HCR) were determined in each patient. After preliminary
baseline analyses, it was decided to determine serum B12
from serum samples that had been stored at -20°C on the
six-month follow-up.
Serum vitamin B12  and erythrocyte folate levels were
determined using time-resolved fluoroimmunoassays in
the laboratory of Kuopio University Hospital. Reference
ranges, which were provided by the laboratory, were 140
– 540 pmol/l for a normal serum vitamin B12 level and
315 – 850 nmol/l for a normal erythrocyte folate level.
Levels below these ranges were defined as low, and above
these ranges as high.
The level of depression was assessed using the 17-item
Hamilton Depression Rating Scale (HDRS) both at base-
line and after six months [17]. Cronbach's alpha for
HDRS ratings was 0.74 at baseline and 0.81 on follow-up.
The mean HDRS score at baseline was 18.8 (SD 6.5), and
the mean decline in the HDRS score during the study
period was 6.8 (SD 7.4). The treatment outcome was
defined in the following manner: a full response was
defined as a reduction of more than 50% in the HDRS
score between baseline and follow-up, a partial response
as a reduction of between 25 and 50%, and nonresponse
as a reduction of less than 25% [18]. Symptoms of weight
loss and gastrointestinal symptoms, including poor appe-
tite, were derived from HDRS ratings for statistical
analyses.
For this study the patients were interviewed at baseline
and on 6-month follow-up. During the study period they
were treated by their regular outpatient psychiatrists and
therapists. Information on the treatment received during
the study period was collected from patients' case notes
and follow-up interviews. The antidepressive medication
used during the study period was considered to be ade-
quate if the length of the treatment exceeded 3 monthsBMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/17
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and if the daily dose used was within the range deemed
efficient (tricyclics ≥ 150 mg, citalopram ≥ 20 mg, fluoxe-
tine ≥ 20 mg and paroxetine ≥ 20 mg) [19,20]. Patients
were asked whether they had had an adjunct therapeutic
relationship during the study period. The frequency and
length of the therapeutic relationship and the presence of
inpatient care received during the follow-up were also
recorded.
Comparisons were made between patients in full
response (n = 40), partial response (n = 34) and nonre-
sponse (n = 41) groups. The statistical methods used were
chi-squared test, Pearson's correlation coefficient, the Stu-
dent's t-test, analysis of variance (ANOVA), and univariate
and multivariate linear regression analysis.
Results
At baseline, no patients had a low vitamin B12 level, while
14 patients (12%) had a high vitamin B12 level. Twenty-
one patients (18%) had a low erythrocyte folate level and
two (2%) had a high level. On follow-up, two patients
(2%) had a low and two (2%) a high vitamin B12 level.
Baseline and 6-month B12 levels correlated significantly (r
= 0.52, p < 0.001).
Haematological indices and the BMI did not correlate
with vitamin B12 or folate levels. Neither were there signif-
icant differences in the levels of vitamin B12 or folate
between patients with and without weight loss or gas-
trointestinal symptoms (data not shown). Furthermore,
haematological indices did not associate with the treat-
ment response (Table 1).
Significant differences were found in B12 levels between
patients in full response, partial response and nonre-
sponse groups (Table 1). The vitamin B12 level and the
HDRS score did not correlate at baseline. Nevertheless, a
positive correlation was found between both the vitamin
B12 level at baseline (r = 0.39, p < 0.001) and on follow-
up (r = 0.26, p = 0.006), and the decline in the HDRS score
during six months of treatment.
There were no significant differences in the erythrocyte
folate level at baseline between full response, partial
response and nonresponse groups (Table 1). Neverthe-
less, the folate level at baseline correlated with both the
baseline HDRS score (r = 0.21, p = 0.021) and the decline
in the HDRS score during the follow-up (r = 0.20, p =
0.037).
The severity of depression (HDRS score) at baseline dif-
fered between full response, partial response and nonre-
sponse groups. The highest score was in the partial
response group. Not surprisingly, a highly significant dif-
ference was also found between the groups in the follow-
up HDRS score (Table 1).
Sixty-four patients (56%) had been on adequate antide-
pressive medication and 83 (72%) had had an adjunct
therapeutic relationship. However, only 49 of them (43%
of the total sample) had been met at least weekly during
three months. Fifteen (13%) had been treated as inpa-
tients during the follow-up period. These treatment varia-
bles did not associate with haematological indices, the
erythrocyte folate level, the serum vitamin B12 level or the
baseline HDRS score (data not shown). Those who were
in nonresponse and partial response groups had been
treated as inpatients more often than those in the full
response group. No other associations were found
between treatment variables and response groups (Table
2).
Table 1: Haematological indices, vitamin B12 and folate, and six-month treatment outcome in major depressive disorder (n = 115)
Nonresponse (n = 40) Partial response (n = 34) Full response (n = 41)
Mean (SD) Mean (SD) Mean (SD)
Haemoglobin (g/l) 141.7 (10.1) 141.1 (13.3) 139.1 (14.8)
Mean corpuscular volume (fl) 92.5 (6.0) 90.4 (5.8) 89.5 (6.6)
Red blood cell count (cell12/l) 4.51 (0.46) 4.57 (0.39) 4.56 (0.42)
Hematocrit (%) 41.6 (3.1) 41.2 (3.7) 40.8 (4.0)
Vitamin B12 at baseline (pmol/l)1 347.2 (103.4) 396.0 (108.4) 439.1 (115.6)
Vitamin B12 on follow-up (pmol/l)2 280.4 (93.3) 316.2 (98.2) 338.8 (87.5)
Folate at baseline (nmol/l) 409.7 (126.0) 431.5 (114.8) 446.8 (244.8)
HDRS score at baseline3 16.8 (7.2) 22.3 (5.6) 17.8 (5.4)
HDRS score on follow-up4 17.6 (4.9) 13.8 (3.7) 4.6 (3.2)
ANOVA: 1 F = 7.17, p = 0.001. 2 F = 4.07, p = 0.02. 3 F = 8.10, p = 0.01. 4 F = 112.58, p < 0.001.BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/17
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Haematological indices did not associate with the decline
in the HDRS score according to linear regression analysis
(data not shown).
The relationship between the baseline vitamin B12 level
and the decline in the HDRS score was found to be posi-
tive and linear in univariate regression analysis (β = 0.39,
t = 4.50, p < 0.001). This relationship remained independ-
ent and significant (β = 0.28, t = 3.40, p = 0.001) even after
adjustment for age (years), sex, duration of the illness
(years), family history of depression (yes/no), patterns of
alcohol use (at least once a week/other), smoking habits
(daily/other), BMI (kg/m2), weight loss (less than 3 kg, 3–
5 kg, 5–8 kg, over 8 kg), gastrointestinal symptoms (yes/
no), severity of depression at baseline (HDRS score), ade-
quate drug treatment (yes/no), weekly psychotherapy
(yes/no) and inpatient treatment (yes/no). For the follow-
up vitamin B12 level the figures were also statistically sig-
nificant (univariate β = 0.26, t = 2.80, p = 0.006 and mul-
tivariate β = 0.24, t = 2.85, p = 0.006, respectively).
The baseline folate level and decline in the HDRS score
associated weakly in univariate linear regression analysis
(β = 0.20, t = 2.11, p = 0.037), but the association was no
more significant when adjusted for other variables
included in the multivariate analyses (β = 0.08, t = 0.87, p
= 0.389).
Discussion
As far as we know, there have been no previous studies
that have suggested a positive relationship between the
vitamin B12 level and the treatment outcome in patients
with major depressive disorder who generally have nor-
mal or high serum vitamin B12 levels. Previous research
has focused on possible associations between a low vita-
min B12 level and a poor treatment response [9]. A low
vitamin B12 level was less common in our sample than has
been previously reported in patients with major depres-
sion [21]. We found no correlation between the severity of
depression and the level of vitamin B12  at baseline,
although the folate level and severity of depression dis-
played a weak positive correlation. Engström et al. [22]
found no correlation between the levels of folate or B12
and the severity of depression, but an inverse relationship
between the level of folate and severity of depression has
been reported in some other studies [3,9].
A low folate level was relatively common (18%) among
our patients with major depressive disorder, which is in
accordance with previous studies [23]. Nevertheless, a low
folate level was not detected in German or Chinese
patients with major depression [24,25]. We observed only
weak indications that a low erythrocyte folate level might
be associated with the poor treatment outcome, which is
contradictory to some previous studies [4,9,10]. It could
be that culturally defined dietary habits influence the rela-
tionship between the folate status and depression in dif-
ferent societies [25]. Recently it was reported that low
dietary folate and depressive symptoms are associated in
middle-aged Finnish men [26]. Moreover, our study
included only young and middle-aged outpatients with
moderate depression, which may have influenced the
results. The association between folate and depression
may be more prominent in elderly subjects, among whom
folate deficiency has been relatively common in some
studies [27].
Poor appetite and inappropriate food intake as symptoms
of depression could result in low levels of vitamin B12 and
especially low levels of folate. However, we found no con-
nection between BMI, HDRS items relating to gastrointes-
tinal symptoms and weight loss, and blood vitamin levels.
Why some depressed people have lower levels of these
vitamins could be a topic for further investigation. It
might reflect to a lower intake of vitamins from food or
assimilation from the gastrointestinal track, or a higher
rate of metabolism of these vitamins. Depression may
also affect the quality of food in the diet. Morris and co-
workers [7] found that levels of blood folate had
decreased after an episode of depression. However, loss of
appetite, weight loss and being underweight were not
related to folate levels.
Table 2: Treatment variables and six-month outcome in major depressive disorder (n = 115)
Nonresponse (n = 40) Partial response (n = 34) Full response (n = 41)
N (%) N (%) N (%)
Adjunct therapeutic relationship 30 (73) 24 (71) 29 (73)
Weekly psychotherapy1 20 (49) 11 (32) 18 (45)
Adequate drug therapy2 26 (63) 20 (59) 18 (45)
Treated as an inpatient3 9 (22) 5 (15) 1 (3)
1 Duration at least three months. 2 See definition in the Methods section. 3 Chi-Squared 6.87, df 2, p = 0.032.BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/17
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There are several theories concerning potential associa-
tions between depression and levels of vitamin B12 and
folate. Vitamin B12 and folate are connected with the syn-
thesis of monoamines and are involved in single carbon
transfer methylation reactions connected with the produc-
tion of monoamine neurotransmitters [28]. Low levels of
5-hydroxyindole acetic acid (5-HIAA) in cerebrospinal
fluid (CSF) have been found in depressed patients with
folate deficiency [29]. However, Engström et al. [22]
found no correlation between levels of 5-HIAA in the CSF
and vitamin B12 or folate levels.
Vitamin B12 deficiency may also result in the accumula-
tion of homocysteine, which has been suggested to lead to
exito-toxic reactions and may enhance depression
[30,31]. Bottiglieri et al. [32] found raised levels of homo-
cysteine in 52% of depressed inpatients. Vitamin B12 is
also required in the synthesis of S-adenosylmethionine
(SAM), which is needed as a methyl donor in many meth-
ylation reactions in the brain. It has been also suggested to
have antidepressant properties [33].
We observed no correlation between vitamin B12 and
folate levels and the mean corpuscular volume, red blood
cell count or hematocrit, which is in line with previous
studies [5,21]. Haematological indices did not predict the
treatment outcome, either. This indicates that haemato-
logical indices have no value in assessing depressed
patients, while the levels of vitamin B12 in serum and
folate in erythrocytes may have.
Multivariate analyses adjusted for age, sex, the family his-
tory of depression, the duration of the illness, severity of
depression at baseline and treatment variables during the
follow-up period supported the existence of an independ-
ent relationship between the vitamin B12 level and decline
in the HDRS score. This was, however, a naturalistic fol-
low-up study, and sociodemographic and clinical and
treatment variables were not controlled a priori. This is
the main shortcoming of our study. We suggest further
studies with controlled illness and treatment variables to
confirm or to refute our findings.
Our sample included more women (61%) than men, only
one subject was aged over 65 years and 87% had only
been treated as outpatients. All these variables may influ-
ence the results. Men and women may have different die-
tary habits. A low folate intake is common among Finnish
men [26]. A low vitamin B12 level and B12 deficiency have
been found to be common among older women [5], but
elderly men may have even lower B12 levels [34]. Finally,
patients with psychotic depression may have lower B12
levels than non-psychotic depressives [35]. Psychotic
depression is a common indication for inpatient treat-
ment. For all these reasons one should be careful about
generalizing these findings to all groups of depressive
patients.
The mean level of vitamin B12 on follow-up was lower
than at baseline, which may indicate some deterioration
of the samples during freezing. Previously, Kirke et al.
have reported that levels of folate may decline by approx-
imately 20% during six years of freezing [36]. The length
of the storage had little effect on this deterioration.
Another explanation is that depression may also affect the
quality of food in the diet which lowers levels of blood
vitamins during an episode of depression [7]. Neverthe-
less, baseline and follow-up levels of vitamin B12 in the
present study correlated significantly and both also asso-
ciated highly significantly with the decline in the HDRS
level during the follow-up, which supports our findings.
Conclusions
The results of this and previous studies together suggest
that the associations between folate, vitamin B12  and
depression remain unresolved. It is possible that there are
several biological pathways leading to major depressive
disorder, which is still defined as a cluster of unspecific
clinical symptoms. Further epidemiological and clinical
studies on the associations between folate, vitamin B12
and depressive disorders are suggested. It is possible that
safe augmentation strategies for antidepressive treatments
could be found.
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